Urology
Volume 70, Issue 6, Supplement 1 , Pages S42-S44, December 2007

Group Consensus Reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006

  • David G. Bostwick

      Affiliations

    • Bostwick Laboratories, Richmond, Virginia, USA
    • Corresponding Author InformationReprint requests: David G. Bostwick, MD, Bostwick Laboratories, Office of Medical Director, 4355 Innslake Drive, Glen Allen, Virginia 23060.
    • Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
    • Dr. Bostwick is a study investigator for Bioniche, Dendreon, DiagnoCure, Endocare, Genotherapeutics, GlaxoSmithKline, and Health Tronics; and is the founder and majority shareholder in Bostwick Laboratories.
    • ,
  • David J. Waters

      Affiliations

    • Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
    • ,
  • Edward R. Farley

      Affiliations

    • Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
    • ,
  • Isabelle Meiers

      Affiliations

    • Report of Consensus Group 1: Pathobiology of Prostate Cancer: Implications for Focal Therapy
    • ,
  • Daniel Rukstalis

      Affiliations

    • Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
    • ,
  • William A. Cavanaugh

      Affiliations

    • Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
    • ,
  • Haakon Ragde

      Affiliations

    • Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
    • ,
  • Martin K. Dineen

      Affiliations

    • Report of Consensus Group 2: Definition and Rationale of Focal Therapy for Prostate Cancer
    • ,
  • Duke Bahn

      Affiliations

    • Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
    • ,
  • Stephen Scionti

      Affiliations

    • Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
    • ,
  • Richard Babian

      Affiliations

    • Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
    • ,
  • David S. Ellis

      Affiliations

    • Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
    • ,
  • John C. Rewcastle

      Affiliations

    • Report of Consensus Group 3: Patient Selection Factors for Focal Therapy for Prostate Cancer
    • ,
  • Harry B. Burke

      Affiliations

    • Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
    • ,
  • Gerald L. Andriole

      Affiliations

    • Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
    • ,
  • Gary Onik

      Affiliations

    • Department of Radiology and Urology, Division of Surgical Imaging, Center for Surgical Advancement, Celebration Health/Florida Hospital, Celebration, Florida, USA
    • Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
    • Dr. Onik holds stock in Endocare, Inc.
    • ,
  • Al E. Barqawi

      Affiliations

    • Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
    • ,
  • John Maksem

      Affiliations

    • Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy
    • ,
  • Winston E. Barzell

      Affiliations

    • Report of Consensus Group 4: 3-Dimensional Prostate Mapping Biopsies for Patients Being Considered for Focal Therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0090-4295(07)01814-6

doi:10.1016/j.urology.2007.07.037

Urology
Volume 70, Issue 6, Supplement 1 , Pages S42-S44, December 2007

Article Tools